SANN Statistics

Total Valuation

Santhera Pharmaceuticals Holding AG has a market cap or net worth of CHF 108.88 million. The enterprise value is 100.06 million.

Market Cap	108.88M
Enterprise Value	100.06M

Important Dates

The next estimated earnings date is Thursday, September 12, 2024.

Earnings Date	Sep 12, 2024
Ex-Dividend Date	n/a

Share Statistics

Santhera Pharmaceuticals Holding AG has 11.72 million shares outstanding. The number of shares has increased by 0.42% in one year.

Shares Outstanding	11.72M
Shares Change (YoY)	+0.42%
Shares Change (QoQ)	-11.82%
Owned by Insiders (%)	0.48%
Owned by Institutions (%)	11.07%
Float	8.67M

Valuation Ratios

The trailing PE ratio is 1.85.

PE Ratio	1.85
Forward PE	n/a
PS Ratio	0.95
PB Ratio	1.75
P/FCF Ratio	2.31
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 1.85, with an EV/FCF ratio of 2.12.

EV / Earnings	1.83
EV / Sales	0.97
EV / EBITDA	1.85
EV / EBIT	1.96
EV / FCF	2.12

Financial Position

The company has a current ratio of 0.78, with a Debt / Equity ratio of 35.95.

Current Ratio	0.78
Quick Ratio	0.73
Debt / Equity	35.95
Debt / EBITDA	0.40
Debt / FCF	0.46
Interest Coverage	2.40

Financial Efficiency

Return on equity (ROE) is 673.95% and return on invested capital (ROIC) is 77.76%.

Return on Equity (ROE)	673.95%
Return on Assets (ROA)	36.89%
Return on Capital (ROIC)	77.76%
Revenue Per Employee	2.30M
Profits Per Employee	1.22M
Employee Count	45
Asset Turnover	1.19
Inventory Turnover	3.37

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +8.64% in the last 52 weeks. The beta is 0.12, so Santhera Pharmaceuticals Holding AG's price volatility has been lower than the market average.

Beta (5Y)	0.12
52-Week Price Change	+8.64%
50-Day Moving Average	8.86
200-Day Moving Average	9.47
Relative Strength Index (RSI)	53.28
Average Volume (20 Days)	13,183

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Santhera Pharmaceuticals Holding AG had revenue of CHF 103.41 million and earned 54.78 million in profits. Earnings per share was 5.01.

Revenue	103.41M
Gross Profit	100.18M
Operating Income	51.16M
Pretax Income	54.82M
Net Income	54.78M
EBITDA	53.76M
EBIT	51.16M
Earnings Per Share (EPS)	5.01

Full Income Statement

Balance Sheet

The company has 30.37 million in cash and 21.55 million in debt, giving a net cash position of 8.82 million or 0.75 per share.

Cash & Cash Equivalents	30.37M
Total Debt	21.55M
Net Cash	8.82M
Net Cash Per Share	0.75
Equity (Book Value)	59.94M
Book Value Per Share	5.30
Working Capital	-9.66M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 47.27 million and capital expenditures -90,000, giving a free cash flow of 47.18 million.

Operating Cash Flow	47.27M
Capital Expenditures	-90,000
Free Cash Flow	47.18M
FCF Per Share	4.03

Full Cash Flow Statement

Margins

Gross margin is 96.87%, with operating and profit margins of 49.47% and 52.97%.

Gross Margin	96.87%
Operating Margin	49.47%
Pretax Margin	53.01%
Profit Margin	52.97%
EBITDA Margin	51.99%
EBIT Margin	49.47%
FCF Margin	45.62%

Dividends & Yields

Santhera Pharmaceuticals Holding AG does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.42%
Shareholder Yield	-0.42%
Earnings Yield	53.93%
FCF Yield	43.33%

Stock Splits

The last stock split was on July 3, 2023. It was a reverse split with a ratio of 0.1.

Last Split Date	Jul 3, 2023
Split Type	Reverse
Split Ratio	0.1